Recurrent Aphthous Stomatitis
Conditions
Keywords
recurrent aphthous stomatitis, chlorhexidine, hyaluronic acid, pain, topical
Brief summary
This study was conducted to estimate the hypothesis that the topical hyaluronic acid mouthwash have no role in the treatment of recurrent aphthous stomatitis
Detailed description
Recurrent aphthous stomatitis (RAS) is a common and widely recognized disorder involving the oral mucosa. It occurs typically as a single or multiple well-defined painful self-limiting ulcerative lesions influencing the nonkeratinized oral mucous membrane surrounded by red halo. The prevalence of RAS is up to 25% in the world population, with recurrence rate of 50% every 3 mouths. The exact cause of RAS is uncertain, and accordingly numerous components are as yet being implicated such as genetic, hormonal, traumatic, nutritional, allergic, immunological, and psychological factors.
Interventions
DRUGHyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Masking description
The clinical outcomes were assessed by an investigator masked about the treatment modality that has been used
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
The inclusion criteria were as follows: * Age 18-30 years. * Minimum of 2 years of RAS history, with active ulcer less than 48 hours of recurrent aphthous stomatitis.
Exclusion criteria
* known history of hypersensitivities to Chlorhexidine or hyaluronic acid. * Use of any medication as a treatment for the present active ulcer. * Smoking and presence of systemic diseases such as Behçet disease, anemia, Crohn's disease, ulcerative colitis, acquired immune deficiency syndrome, and liver or kidney disease. * Pregnant or breast-feeding women. * Stomach ulcer, duodenal ulcer, and inflammation of the stomach or the esophagus. * Treatment with systemic nonsteroidal anti-inflammatory drugs, systemic steroids or other immune modulatory agents, oral antihistamines, or systemic antibiotics in the previous 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | one week | Pain assessment scale, visual analog scale (VAS) comprising of a 10-cm straight line among ends, with 0 representing no pain (better outcome) and 10 for intolerable pain (worse outcome) after irritation of the ulcer with the periodontal probe. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ulcer size | one week | The ulcer size was evaluated by determining the distance between two opposed boundaries of the ulcer edge, using a periodontal probe in millimeters.Score for clinical improvement of the sign where high values indicate worse outcome but low values indicate better outcome. |
| Duration of healing | one week | period of the ulceration for complete healing |
Countries
Egypt
Outcome results
None listed